Cetuximab biosimilar (Guilin Sanjin)

西妥昔单抗生物类似药（桂林三金）

Report date: 2022/04/01 17:07:24

Base Information

Drug NameCetuximab biosimilar (Guilin Sanjin)
Drug Alias NameRecombinant chimeric anti-EGFR monoclonal antibody (Guilin Sanjin&Baochuan Biological)重组抗EGFR人鼠嵌合单克隆抗体（桂林三金&宝船生物）Recombinant anti-EGFR chimeric monoclonal antibody (Guilin Sanjin&Baochuan Biological)西妥昔单抗生物仿制药（桂林三金&宝船生物）Recombinant anti-EGFR monoclonal antibody (Guilin Sanjin&Baochuan Biological) +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Biosimilar
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsSolid tumoursColorectal NeoplasmsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesGuilin Sanjin Pharmaceutical Co LtdDragonboat Biopharmaceutical
China Registration ClassN/A

Develop Information

Active CompaniesDragonboat BiopharmaceuticalGuilin Sanjin Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsColorectal NeoplasmsNeoplasms

Other Information

ATC CodeL01XC06
Related LinksN/A